KEGG   DRUG: Nemolizumab
Entry
D11080                      Drug                                   
Name
Nemolizumab (USAN/INN);
Nemolizumab (genetical recombination) (JAN);
Mitchga (TN)
Formula
C6384H9814N1678O2034S48
Exact mass
144064.2688
Mol weight
144153.3742
Sequence
(Heavy chain)
QVQLVQSGAE VKKPGASVKV SCKASGYTFT GYIMNWVRQA PGQGLEWMGL INPYNGGTDY
NPQFQDRVTI TADKSTSTAY MELSSLRSED TAVYYCARDG YDDGPYTLET WGQGTLVTVS
SASTKGPSVF PLAPSSKSTS GGTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS
SGLYSLSSVV TVPSSNFGTQ TYTCNVDHKP SNTKVDKTVE RKSCVECPPC PAPPVAGPSV
FLFPPKPKDT LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTF
RVVSVLTVVH QDWLNGKEYK CKVSNKGLPA PIEKTISKTK GQPREPQVYT LPPSQEEMTK
NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPMLDS DGSFFLYSKL TVDKSRWQEG
NVFSCSVMHE ALHNHYTQKS LSLSP
(Light chain)
DIQMTQSPSS LSASVGDRVT ITCQASEDIY SFVAWYQQKP GKAPKLLIYN AQTEAQGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQH HYDSPLTFGG GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H96, H148-H204, H224-L214, H227-h227, H230-h230, H261-H321, H367-H425, h22-h96, h148-h204, h224-l214, h261-h321, h367-h425, L23-L88, L134-L194, l23-l88, l134-l194)
  Type
Peptide
Class
Immunological agent
 DG02019  Interleukin inhibitor
Dermatological agent
 DG03243  Atopic dermatitis agent
Remark
Therapeutic category: 4490
ATC code: D11AH12
Product: D11080<JP>
Efficacy
Anti-inflammatory, Antipruritic, Anti-IL-31 receptor antibody
  Type
Monoclonal antibody
Comment
Treatment of atopic dermatitis (AD), treatment of prurigo nodularis (PN) and chronic kidney disease associated pruritus (CKD-aP)
Target
IL31RA [HSA:133396] [KO:K22630]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 D DERMATOLOGICALS
  D11 OTHER DERMATOLOGICAL PREPARATIONS
   D11A OTHER DERMATOLOGICAL PREPARATIONS
    D11AH Agents for dermatitis, excluding corticosteroids
     D11AH12 Nemolizumab
      D11080  Nemolizumab (USAN/INN) <JP>
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  44  Allergic agents
   449  Miscellaneous
    4490  Miscellaneous
     D11080  Nemolizumab (USAN/INN); Nemolizumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Immunological agent
  DG02019  Interleukin inhibitor
   D11080  Nemolizumab
 Dermatological agent
  DG03243  Atopic dermatitis agent
   D11080  Nemolizumab
Drug classes [BR:br08332]
 Immunological agent
  DG02019  Interleukin inhibitor
   D11080  Nemolizumab
 Dermatological agent
  DG03243  Atopic dermatitis agent
   D11080  Nemolizumab
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   Interleukin receptors
    IL31RA
     D11080  Nemolizumab (USAN/INN) <JP>
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11080
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11080
Other DBs
CAS: 1476039-58-3
PubChem: 375581027
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system